US Edition
Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term Use, Highlights Psychedelic Opportunity; MAHA Report Slams Psychiatric Meds; Momentum Builds for Beckley - Psychedelic Alpha
Summary by psychedelicalpha.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term Use, Highlights Psychedelic Opportunity; MAHA Report Slams Psychiatric Meds; Momentum Builds for Beckley - Psychedelic Alpha
Earlier this month, a manuscript by Zaki et al. (2025) looked at the long-term safety and efficacy of esketamine nasal spray (Spravato) in treatment-resistant depression (TRD). It provides an unprecedented look at how the product is used over the medium and long term, such as average treatment duration, reasons for discontinuation, and outcomes. The data is derived… Source
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage